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Abstract: Background: Clinically silent cerebral ischemia (SCI) detected by diffusion-weighted MRI has 
been reported in 5-40% of patients undergoing pulmonary vein isolation (PVI). Although initial reports 
suggested a high rate of SCI with phased radiofrequency (RF) ablation on use of the pulmonary vein 
ablation catheter (PVAC), the incidence was subsequently markedly reduced in consequence of 
procedural modifications in recent studies.  
 We analyzed cerebral microembolization as assessed with transcranial Doppler during phased 
RF ablation and with two other single-shot AF ablation technologies: the cryoballoon (CB) and the 
nMARQTM multipolar irrigated RF ablation system.   
 Methods and results: A total of 89 patients (mean age: 57, SD: 12 years; 62 male) with 
paroxysmal or persistent AF, underwent PVI. Phased RF was used according to the initial protocol in 7 
patients (PVAC Group I), with procedural modifications and a newer (14.4) version of the RF generator 
in 37 patients (PVAC Group II) and with the most recent (version 15.0) generator in 18 patients (PVAC 
Group III). Ablation was performed with the CB in 13  and with the nMARQ system in 14 patients.  
 The number of microemboli (mean+(SD) detected in the middle cerebral arteries was 
2703(918)  in PVAC Group I, 1087(542)  in PVAC Group II, 719(469) in PVAC Group III, 1057(784) 
with CB and 2166(1047) with nMARQ (p<0.01). 
 Conclusion: Significant decreases in MES counts were observed thanks to the procedural 
modifications and newer RF generator with phased RF. High MES counts comparable to those with the 
initial phased RF resulted from the use of nMARQ.  
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ABSTRACT  
 
 Background: Clinically silent cerebral ischemia (SCI) detected by diffusion-weighted 
MRI has been reported in 5-40% of patients undergoing pulmonary vein isolation (PVI). 
Although initial reports suggested a high rate of SCI with phased radiofrequency (RF) 
ablation on use of the pulmonary vein ablation catheter (PVAC), the incidence was 
subsequently markedly reduced in consequence of procedural modifications in recent studies.  
 We analyzed cerebral microembolization as assessed with transcranial Doppler during 
phased RF ablation and with two other single-shot AF ablation technologies: the cryoballoon 
(CB) and the nMARQ
TM
 multipolar irrigated RF ablation system.   
 Methods and results: A total of 89 patients (mean age: 57, SD: 12 years; 62 male) with 
paroxysmal or persistent AF, underwent PVI. Phased RF was used according to the initial 
protocol in 7 patients (PVAC Group I), with procedural modifications and a newer (14.4) 
version of the RF generator in 37 patients (PVAC Group II) and with the most recent (version 
15.0) generator in 18 patients (PVAC Group III). Ablation was performed with the CB in 13  
and with the nMARQ system in 14 patients.  
 The number of microemboli (mean+(SD) detected in the middle cerebral arteries 
was 2703(918)  in PVAC Group I, 1087(542)  in PVAC Group II, 719(469) in PVAC Group 
III, 1057(784) with CB and 2166(1047) with nMARQ (p<0.01). 
 Conclusion: Significant decreases in MES counts were observed thanks to the 
procedural modifications and newer RF generator with phased RF. High MES counts 
comparable to those with the initial phased RF resulted from the use of nMARQ.  
 
 
 
  
  
Introduction  
 
 Pulmonary vein (PV) isolation (PVI) is an established method for the treatment of 
atrial fibrillation (AF), with a relatively low risk (<1%) of major periprocedural 
complications, including clinical stroke or transient ischemic attack (TIA) [1].
 
However, 
significant concern has been raised regarding the long-term safety of PVI as clinically silent 
cerebral ischemia (SCI) detected by diffusion-weighted (DW) MRI has been reported in 5-
40% of the patients, depending on the ablation technology used [2-8].
 
Further, the limited data 
available suggest that a cognitive decline potentially related to SCI can be demonstrated 
several months after these ablations in some patients. In some studies, a markedly higher 
incidence of SCI was reported after PVI performed with phased radiofrequency (RF) and the 
PV ablation catheter (PVAC), as compared with the cryoballoon (CB) or focal irrigated RF 
ablation [2,3]. More recent reports with phased RF ablation, however, demonstrated a 
significant decrease in the incidence of SCI, these favourable results were attributed to the use 
of more rigorous periprocedural anticoagulation protocols and some specific modifications in 
the procedural technique [9-11]. These procedural changes were based on the results of 
animal studies [12, 13] and included the avoidance of overlap between 2 electrodes during RF 
applications and careful sheath management to prevent air embolization. Software 
modifications refining the power handling of the GENius RF generator have also been 
implemented.  
  The recording of microembolic signals (MESs) in the middle cerebral arteries (MCAs) 
by transcranial Doppler (TCD) has been used to assess microembolization during different 
cardiovascular procedures [14-16]. Although DW MRI is regarded as the gold standard for 
the demonstration of cerebral lesions post-ablation, recording of the MESs provides a unique 
opportunity through which to monitor the intensity of microembolus generation during 
different phases of the procedure. In line with the initial DW MRI results, when we used the 
  
earlier version of the GENius generator we detected a significantly higher number of MESs 
during ablation with the PVAC as compared with the CB [17]. Further, we demonstrated that 
the majority of the microemboli were generated during the energy delivery (ED) with phased 
RF ablations, while the rate of microembolization was relatively uniform throughout the 
procedure with the CB. Whether the procedural and technical modifications which decreased 
lesion formation on DW MRI with the phased RF technology would also reduce the 
microembolization detected by TCD is unknown.   
 Phased RF ablations with the PVAC have been performed for 5 years in our center, 
using subsequent versions of the GENius RF generator together with specific procedural 
modifications to improve safety as suggested by the literature data. MESs are detected with 
TCD routinely during all AF procedures in our laboratory. In this study, we analysed our 
TCD data obtained with phased RF ablations in relation to the procedural changes 
implemented in recent years. In order to view these results in context with other single-shot 
AF ablation technologies designed for fast and simplified PVI, we have compared the MES 
data with those obtained by using the CB and the novel nMARQ
TM
 (Biosense Webster, Inc., 
Diamond Bar, CA, USA) multipolar irrigated RF ablation system.   
 
Methods 
 
Patients 
 
 Consecutive patients undergoing PVI for symptomatic paroxysmal or 
persistent AF not adequately controlled by at least one antiarrhythmic drug were considered 
for inclusion in the study. Exclusion criteria included long-standing persistent AF, hyper- and 
  
hypothyroidism, significant valvular heart disease, heart failure of NYHA class III or IV, a 
left ventricular (LV) ejection fraction ≤ 40%, a left atrial (LA) diameter exceeding 50 mm, a 
LA thrombus, unstable angina or myocardial infarction within the last 3 months, severe 
chronic obstructive pulmonary disease, known bleeding disorders, a contraindication to oral 
anticoagulation and pregnancy. All participating patients provided their signed informed 
consent prior to the procedure. 
 Further prerequisites for inclusion in this study were as follows:  
1. Pre-ablation treatment with a vitamin K antagonist (VKA) for a minimum of 3 weeks and a 
therapeutic (above 2.0) international normalized ratio (INR) confirmed on the day of the 
procedure, and activated clotting time (ACT) levels above 300 s during ablations.  
2. Bi- or unilateral TCD recordings of sufficient quality of the Middle Cerebral Artery (MCA) 
throughout the LA access period. 
3. Ablation  performed with one of 3 single-shot technologies designed for PVI: phased RF, 
CB or nMARQ. As PVI with phased RF and the PVAC was performed with the use of 3 
different versions of the GENius generator, and this was also accompanied by significant 
procedural modifications, the MES data acquired with this technology were analyzed 
separately in 3 treatment groups (PVAC Groups I, II and III). 
 
 
Pre-ablation evaluation and LA catheterization 
 
 Patients were admitted to the hospital 1 or 2 days prior to the procedure. 
Transesophageal echocardiography was performed to exclude the presence of an intracardiac 
  
thrombus within 24 h before the ablation. All patients received oral anticoagulation before the 
PVI, with a target INR of 2.0 to 3.0. 
 All procedures were performed under conscious sedation with midazolam and 
fentanyl. Decapolar (BARD Electrophysiology Inc., Lowell, MA, USA) and quadripolar 
(Woxx 4 J, 6F, Biotronik, SE & Co. KG, Berlin, Germany) catheters were advanced from the 
femoral vein and positioned into the coronary sinus and the right ventricle. Surface 
electrocardiograms and bipolar intracardiac electrograms were registered with a Prucka, GE 
Medical digital recording system. A single transseptal puncture was performed under 
fluoroscopic, or in some cases under intracardiac echocardiographic (ICE) guidance, using a 
Brockenbrough needle (St. Jude, Inc., Zaventem, Belgium) and a Swartz sheath (St. Jude, 
Zaventem, Belgium). This sheath was exchanged for the deflectable 12 Fr FlexCath sheath 
(Medtronic CryoCath LP, Kirkland, Quebec, Canada), which was flushed continuously with 
heparinized saline, and which was used with any of the ablation catheters utilized in this 
study. Immediately after the transseptal puncture, a 150 IU/kg body weight intravenous (iv) 
heparin bolus was administered, followed by a continuous infusion to maintain a minimum 
ACT target level of 300 s during ablations. Additional 2000-5000 IU iv boluses of heparin 
were administered as needed to attain the minimum target ACT level. 
 
Ablation techniques  
 
Phased RF ablation  
 
 The technical specifications of the PVAC
 
and the GENius RF generator (Medtronic 
Inc., Minneapolis, MN, USA) have been described in detail [17-20]. The  catheter  was 
advanced through the FlexCath sheath over a 0.032-inch guidewire (BARD 
  
Electrophysiology Inc., Lowell, MA, USA), which was positioned selectively in each PV. The 
electrical conduction properties of the PV were assessed on the basis of the signals recorded 
by the PVAC electrodes after placement inside the ostium. Before the first RF application  at 
each PV, the positions of the electrodes relative to the PV ostium were always confirmed by 
means of contrast injection through the FlexCath sheath. Care was always taken to apply the 
RF outside the PV  in the antral region, targeting potentials of high amplitude on as many 
electrodes as possible for each application. RF energy was applied for 60 s, usually 3-4 times 
per PV, until PVI was achieved.  The target temperature was 60 
°
C, measured separately for 
all bipoles. Any electrode pair that failed to reach at least 50 
°
C during RF delivery was 
switched off  to avoid ineffective ED due to improper contact at the electrode-tissue interface. 
Common ostia were isolated by inserting the guidewire into the different side branches and 
ablating subsequent segments of the targeted veins. The PV conduction was reassessed after 
each RF application, the electrodes being advanced inside the ostium.  The endpoint of the 
procedure was the electrical isolation of all PVs, as confirmed by an entrance block. 
 The GENius RF generator is capable of delivering RF in a duty-cycled mode with 
different bipolar/unipolar ratios to any or all of the electrodes on the PVAC. Three 
consecutive versions of the GENius RF generator (Medtronic Inc. , Minneapolis, MN, USA) 
were used in the course of recent years, also coupled with some procedural modifications as 
follows: 
  
1. PVAC Group I. Initial series of ablations were performed with the use of software version 
14.3 for the GENius generator. Bipolar/unipolar RF application was started at a ratio of 4:1 
for each PV and changed to a bipolar/unipolar ratio of 2:1 for a deeper lesion when a 
sufficient reduction in local electrogram amplitude could not be achieved after multiple RF 
  
deliveries. No attempts were made to avoid the potential interaction between the first and the 
last electrode (E1-E10) in the PVAC.   
 
2. PVAC Group II. Ablations were performed with software version 14.4 for the GENius  
generator. Modifications in the procedural technique were implemented in this group of 
patients as follows. Potential interaction between the most distal (E1) and the most proximal 
(E10) electrodes was considered and simultaneous EDs on these poles were attempted only 
after fluoroscopic assessment of the interelectrode distance, which was considered adequate if 
the space between E1 and E10 was at least double the fixed 3-mm interelectrode distance as 
assessed from multiple projections. Furthermore, ablations were started in the 2:1 mode and 
changed to 1:1 in those rare instances when adequate amplitude change and PVI could not be 
achieved after multiple RF applications. In addition, the distal circular segment of the PVAC 
catheter was submerged and captured by the introduction device in a saline bath prior to 
insertion into the FlexCath sheath. This maneuver was used to prevent air entrapment around 
the array and the introduction of air into the LA through the transseptal sheath.   
 
3. PVAC Group III. Ablations were performed using the most recent software version 
(15.0) for the GENius generator. RF delivery to E10 is not supported by this software thereby 
excluding the possibility of E1-E10 interaction. No procedural modifications as compared to   
those in PVAC Group II. were implemented during these ablations. 
 
CB ablation 
 
 The technology of CB ablation has been described in detail [17].  In brief, a 28-mm 
CB was used in all cases. The CB was introduced into the PV ostium over an inner lumen 
  
mapping catheter (Achieve, Medtronic Ablation Frontiers LCC, Carlsbad, CA, USA) which is 
capable of mapping PV potentials before, during and after cryo applications. The best 
possible occlusion of the PVs was facilitated by the steerable sheath and by positioning the 
guidewire in a PV branch to provide maximal support. Furthermore, all special maneuvers 
described previously, such as the “pull-down” or the “hockey stick” techniques,  were used as 
needed [21]. 
 PV occlusion was assessed by means of a hand-held injection of contrast medium 
(Optiray Covidien Deutschland GmbH, Neustadt/Donau, Germany) through the injection 
side-port of the Arctic Front catheter. A minimum of two 5-min freezing cycles were applied 
per PV.  The balloon was repositioned for each application, preferably with the guidewire 
situated in a different branch of the PV in order to maximize the effect of freezing at different 
aspects of the ostium. Before the start of ablation of the septal veins, a quadripolar catheter 
was placed in the superior caval vein, where constant capture of the right phrenic nerve could 
be achieved. One stimulus at maximal output was delivered every 5 s, with manual 
assessment of the diaphragmatic movement. The freezing cycle was terminated immediately 
if loss or weakening of the diaphragm response occurred.  PVI was assessed on the basis of  
the signals recorded by the Achieve wire.   
 
 
nMARQ ablation   
 
 The nMARQ™ (Biosense Webster, Inc., Diamond Bar, CA, USA) is a multi-
electrode, irrigated RF ablation catheter with a uni-directional deflectable tip.  The distal 
tip section is circular or semilunar and contains 10 platinum ring electrodes with irrigation 
holes at both ends for stimulation, recording and ablation. The diameter of the circular or 
  
semilunar loop is variable to accommodate the LA anatomy. The catheter is integrated with 
the CARTO 3 electroanatomical mapping system, which provides mapping and real-time 
navigation capabilities. For ablation, the catheter is used in conjunction with the nMARQ™ 
Multi-Channel RF Generator, which is able to deliver RF simultaneously to multiple 
electrodes in unipolar or bipolar mode. 
 The circular-tip catheter was used exclusively in this study. The catheter was 
advanced to the LA through the FlexCath guiding sheath. The 3-dimensional map of the 
LA was constructed by using the CARTO
TM
 electroanatomical mapping system (Biosense 
Webster, Inc., Diamond Bar, CA, USA) equipped with Cartomerge
TM  
software (Biosense 
Webster, Inc., Diamond Bar, CA, USA). The pre-ablation cardiac CT image of the LA with 
the proximal portions of the PVs was imported and registered for real-time mapping, focusing 
on the PVs and the PV antra of the LA. In addition, the positions of the electrodes relative to 
the PV ostium were always confirmed before the first RF application at each PV, by means of 
contrast injection through the FlexCath sheath. Care was taken to apply the RF outside the PV 
in the antral region, targeting potentials of high amplitude on as many electrodes as possible 
for each application. RF energy was applied for up to a maximum of 60 s at a maximum of 20 
W/electrode in the unipolar mode, with the target temperature set at 43 °C. Electrodes not 
demonstrating the desired rise in temperature up to 40 °C during energy delivery were 
switched off. The irrigation flow rate between RF applications was 4 ml/min, which was 
increased to 60 ml/min, starting 5 s before the onset of RF application and maintained until 
5 s after termination. The electrical conduction properties of the PVs were assessed via the 
recordings through the electrodes of the nMARQ catheter.  The endpoint of the procedure was 
the electrical isolation of all PVs, as confirmed by an entrance block.  
 
  
TCD  recording and evaluation of the MES count 
 
 TCD recording was performed throughout the whole period of LA access (from the 
transseptal puncture to the removal of all catheters and sheaths from the LA). The transducer 
was held in place by a proprietary headpiece supplied with the system. The MCAs were 
bilaterally insonated from transtemporal windows by using a multifrequency Doppler (Multi 
Dop T digital, DWL, QL software 2.8) which insonates simultaneously with frequencies of 2 
and 2.5 MHz. The system is capable of the automatic online identification of true MESs with 
a sensitivity of 100% and a specificity of 99.3% [22], and also of discrimination between 
gaseous and solid emboli with a specificity of 96.5%[23]. The identification of true MESs 
with parallel artefact rejection is possible by implementing an event detector system, using a 
previously published algorithm to detect high-intensity signals due to emboli[22]. This step is 
followed by a second algorithm using data from the dual-frequency insonation to determine 
whether the MESs are to be attributed to a solid or to a gaseous embolus. Differentiation is 
possible because the reflection of ultrasound power is dependent not only on the size of the 
embolus, but also on its composition and the insonating frequency used: solid emboli reflect 
more ultrasound at 2 MHz than at 2.5 MHz, whereas the opposite is true for gaseous emboli. 
TCD parameter settings as recommended by the consensus criteria [24] were kept constant 
during the procedures. The insonation depth was 45-55 mm, the sample volume was 8 mm, 
and the power was 60-100 mW.  An example of a TCD record is given in Figure 1.  MES 
counts were collected and evaluated separately during different stages of the procedure, as 
follows:  
1. Transseptal puncture: the 30-s period after crossing the interatrial septum with the 
transseptal needle. 
  
2. PV angiography: contrast injection through the injection port of the CryoCath catheter or 
the transseptal sheath during PVAC or nMARQ ablation. 
3. Energy delivery: from the start until 15 s after the termination of ED  
4. The remainder of the procedure: that part of the LA access period during which none of the 
aforementioned maneuvers were performed.  
 As bilateral insonation of the MCA could not be achieved in all patients for technical 
reasons, the results were provided as MES count per MCA, i.e. either the mean of bilateral 
recordings or the number from the unilateral recording.   
 
 
Statistical analyses 
 
 Statistical analysis was performed by using IBM SPSS 20. Data are reported as means 
and standard deviation (SD). In the case of Figure 1, data are shown as mean and 95% 
confidence intervals (95% CI). The normality of continuous variables was evaluated by 
means of the Kolmogorov- Smirnov test. Statistical differences between groups were 
determined by using analysis of variance when the data showed normal distribution and 
homoscedasticity (Levene’s statistic); otherwise, the Kruskal-Wallis test was performed. For 
comparison of the MES counts obtained during CB ablation versus those during the other 4 
techniques, the Mann-Whitney test was used. In all statistical tests a p value below 0.05 was 
considered as significant. 
 
Results 
 
  
Patient characteristics 
 
 A total of 89 patients were enrolled in the study. Demographic and clinical parameters 
on the patients in the 5 treatment groups are presented in Table 1. There were no significant 
intergroup differences in the baseline characteristics.   
 
Procedural data 
 
 Procedural data are listed in Table 2. The total procedure, fluoroscopy, ED and LA 
access times demonstrated significant differences. The acute success rates were 100% in the 3 
PVAC Groups, and 98% in both the CB and the nMARQ groups.  The shortest LA access 
time was achieved in PVAC Group III, while the shortest ED time was obtained during 
ablation with the nMARQ.  There were no significant differences between the intraprocedural 
ACT values. Symptomatic thromboembolic event did not occur in any patient.   
 
MES counts 
 
The MES count detected with the CB was used as a reference for comparison with the other 
technologies (Figure 2, left panel). No significant difference was found between the CB 
group, PVAC Group II (p=0.543) and PVAC Group III (p=0.317) in the total cerebral MES 
counts. However significantly higher MES counts were demonstrated in PVAC Group I 
(p=0.005) and with the nMARQ technique (p=0.007). The ratios of gaseous versus solid 
MESs detected in the 5 treatment groups did not differ significantly (p=0.688). (Figure 2, 
right panel) 
  
 The distribution of the MES counts during different stages of the procedure is 
depicted in Figure 3. A relatively even distribution of embolus formation was observed across 
the whole LA access time in the CB group, and in PVAC Groups II and III, whereas, 
microemboli were detected mostly during ED in PVAC Group III and with nMARQ.  
  
Discussion 
 
 Major differences have been reported in the incidence of SCI after AF ablation with 
various technologies and with the different methods and criteria applied to evaluate cerebral 
lesions. The diversity of the periprocedural anticoagulation routine in the various studies 
further hampers a direct comparison of the different AF ablation techniques. In the present 
study, we compared different single-shot ablation tools designed for PVI without additional 
LA ablation (eg. creating long linear lesions, or ablating complex fractionated electrograms) 
in patients with similar baseline characteristics. Further, periprocedural anticoagulation was 
homogeneous across all treatment groups with uninterrupted VKA administration and 
therapeutic INR level before the procedure and iv heparinization to a target ACT above 300 s 
in agreement with current recommendations [25]. Any differences demonstrated in the 
number of microemboli are therefore truly inherent to the ablation techniques compared. 
 The rate of microembolization during phased RF ablation with the implementation of 
specific procedural modifications and the use of consecutive software versions of the GENius 
generator demonstrated a significant decrease in our study. The very same trend was observed 
in recent DW MRI studies on the rate of new SCI lesions after phased RF ablation. 
Importantly, no difference was detected in the level of microembolization between the 
procedure with CB ablation versus that with the PVAC after procedural and software changes 
  
had been implemented (PVAC Groups II and III). In contrast, significantly higher MES 
counts were recorded during phased RF ablation with the use of the old technique (PVAC 
Group I) and during ablation with nMARQ (Figure 2).   
 The significant reduction in microembolization with phased RF was clearly related to 
the elimination of the MESs during the ED period of the procedure. Similarly to as observed 
in PVAC Group I, the majority of the microemboli were generated during ED with nMARQ, 
which also represents a multielectrode RF ablation technology (Figure 3). It is noteworthy 
that MESs were largely gaseous in nature in all treatment groups. 
 
Measures related to the reduction in cerebral embolization with phased RF ablation 
 
 The significant reduction achieved in clinically silent microembolization, as 
demonstrated by DW MRI studies and our own results, were related to refinements in specific 
technical elements of the phased RF ablation, based on preclinical data [12,13].The 
observation of enhanced microembolization with blended unipolar:bipolar energy delivered 
through PVAC electrodes in close proximity to each other was of utmost importance. While 
this problem remained unknown, this was a likely common scenario, owing to the squeezed 
situation of the distal PVAC loop. It should be noted that actual physical contact between any 
two electrodes results in an electrical short circuit and immediate termination of the RF 
delivery. On the other hand, not contact, but a reduced interelectrode space (less than the 
fixed  3 mm between two neighboring electrodes mounted on the distal circular segment of 
the PVAC) may lead to blood and tissue overheating, due to a high current density. Simple 
measures to avoid this possibility include a careful fluoroscopic assessment of the electrode 
positions (as we did in PVAC Group II), exclusion of simultaneous RF ED to electrodes 1 and 
  
10, as proposed by several authors [9-12] and a software modification implemented in the 
latest version of the GENius generator, which supports simultaneous RF delivery to a 
maximum of 9 electrodes (software version 15.0; PVAC Group III in our study). 
 The earlier practice of starting ED in a 4:1 bipolar:unipolar mode at each PV was 
changed to start with a 2:1 ratio in PVAC Groups II and III.  The rationale for this change was 
to avoid extensive bipolar ED and thereby reduce local heating between adjacent electrodes. 
Although animal data suggested a tendency for more microemboli with more bipolar RF 
delivery, the contribution of this change in the reduction of microemboli is uncertain. 
Nonetheless, starting with the 2:1 instead of the 4:1 ratio is the current practice at other 
centers [9-11,26]. 
 As demonstrated in an animal model, a potential source of gaseous emboli was the 
introduction of air into the LA via the transseptal sheath. A significantly larger air volume 
was measured during the introduction of the PVAC, possibly owing to its more complex 
shape as compared with a conventional focal RF catheter.  To prevent air entrapment around 
the array, the PVAC was submerged and captured by the introduction device in a saline bath 
prior to insertion into the FlexCath sheath.  
 It is noteworthy that, in addition to the procedural changes as described above, the 
GENius RF generator has also been modified in recent years. An improved energy titration 
algorithm was implemented starting at version 14.4 (PVAC Group II), which regulates the 
power delivery to control the maximum, instead of the average temperature, with a target of 
60 °C. Further, this software ensures a gradual and limited increase (4 W/s) during variable or 
intermittent electrode-tissue contact, to avoid high temperature peaks. The importance of the 
catheter-tissue contact has been highlighted since the introduction of contact force 
measurement for focal RF ablation catheters [27,28]. With multipolar ablation, this becomes 
even more critical, as the maintenance of good contact simultaneously on multiple electrodes 
  
can be challenging and the capability of direct contact force measurement with this 
technology is not yet available. This concept is supported by our previous study: with an 
analysis of temperature and power data obtained at high resolution sampling from the GENius 
generator, increased microembolus formation was demonstrated during intermittent contact 
scenarios when low temperature was compensated by increased power which resulted in a 
temperature overshoot when the contact was re-established [29]. The latest issue of the 
GENius software (15.0; PVAC Group III) features the energy titration algorithm of version 
14.4, and in addition, RF delivery is limited to 9 electrodes, thereby providing a definite 
solution for the problem of E1-E10 interaction. 
   
Microembolization during CB and nMARQ 
 
 The use of cryoenergy is generally regarded as a more “tissue-friendly” and safer 
ablation technology, which is associated with a significantly lower incidence of thrombus 
formation as compared with RF ablation [30]. The limited data available on 
microembolus generation with CB ablation demonstrated consistent results. The total 
MES count during CB ablation in the present study (1057 SD: 784) was reasonably 
similar (834 SD: 727) to that recorded in our previous work [17], and to that reported by 
Sauren et al. (935 SD: 463 )[31]. Importantly, we also demonstrated that the 
microemboli were predominantly gaseous, with an even distribution throughout the LA 
access period. It should be noted that results obtained on SCI with different AF ablation 
technologies as evaluated with DW MRI are in agreement with these TCD data)[3].  
 Although the results obtained with the nMARQ ablation system reflect our initial 
experience, we found this technology to be very effective with the shortest ED time 
  
required for acutely successful PVI in this study. However, this technology was also 
associated with a high rate of microembolization, of the magnitude of that initially 
achieved with phased RF (PVAC Group I), and significantly higher than the numbers 
obtained with modified phased RF (PVAC Groups II and III) and with CB. Recently 
published results of a German center [32] seem to support our findings: DW MRI 
demonstrated SCI acutely in 14 (33%) out of  43 patients after PVI with the nMARQ 
catheter, a ratio similar to the values up to 39% [2,6] in earlier reports on phased RF 
ablation.  
 The high microembolization rate was somewhat unexpected after the earlier 
experience demonstrating lower incidence of SCI [3] and lower microembolus counts 
[31] with focal irrigated as compared with conventional RF ablation. As a potential 
explanation, one speculative possibility is the irrigation itself used with the nMARQ 
catheter, with a very high rate of 60 ml/min during ED. Direct injection of saline into the 
LA at this rate is known to result in marked bubble formation due to cavitation [33], 
which is readily visible on ICE (as we observed in cases when ICE was used during 
ablations). This mechanism could be responsible for a currently unknown proportion of 
cerebral microemboli. These microemboli are gaseous, which are generally considered 
to be less harmful than solid particles, although their significance in the long-term 
cognitive function is yet to be determined. Other possible causes are likely to be inherent 
to multielectrode ablation and the high total energy delivered when this catheter is used. 
By analyzing biophysical parameters during phased RF ablation [28], our group earlier 
demonstrated that microemboli generation was related to both the number of active 
electrodes during ED and the total energy delivered. Further, maintainenance of a good 
contact on multiple poles throughout the entire duration of RF applications might be 
challenging, and power handling in intermittent contact scenarios could therefore be of 
  
significance. There is an urgent need for more data on embolization rates and in-depth 
investigations into the mechanism with the nMARQ system with the aim of making this 
otherwise promising technology safer.   
 
Limitations 
 
 This was a single-center investigation on a limited number of patients. The study 
was non-randomized and  the data were analysed retrospectively. However, this 
methodology did ensure that the patient characteristics and periprocedural 
anticoagulation were homogeneous, and differences in microembolization therefore 
represented true differences inherent to the ablation techniques compared.   
 
Conclusions 
 
 A significant decrease in the number of microemboli was demonstrated when phased 
RF ablation was implemented with specific procedural modifications with the use of newer 
generations of the GENius RF generator. Microembolus counts were reduced to a level 
comparable with that observed during CB ablation. A significantly higher microembolization 
rate, similar to that recorded with the first version of the GENius generator, was demonstrated 
with the multipolar irrigated nMARQ RF ablation system. 
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TABLE 
 
Table 1. Patient clinical characteristics 
 
Variable CB 
n=13 
PVAC I. 
n=7 
PVAC II. 
n=37 
PVAC III. 
n=18 
nMARQ 
n=14 
p 
Age, years  (SD) 57(15) 54(8) 60(10) 55(12) 53(12) 0.372 
Male, n (%) 9 (69) 6(85) 25(67.5) 12(67) 10(71)  
Type of AF 
Paroxysmal AF, n (%) 
Persistent AF, n (%) 
 
11(84) 
2(16) 
 
6(85) 
1(15) 
 
25(67.5) 
12(32.5) 
 
12(67) 
6(33) 
 
10(71) 
4(29) 
 
Arterial hypertension, n (%) 7(53) 2(28) 28(75) 13(72) 8(57)  
Diabetes mellitus, n (%) 0(0) 2(28) 3(8) 1(5.5) 1(7)  
LA short diameter, mm (SD) 41(4) 40(4) 42(3.5) 43(6) 42(3.7) 0.825 
LVEF, % (SD) 55(4) 52(8) 55(5) 54(10) 58(5) 0.325 
Mean CHADS2 score 0.62 0.71 0.92 0.83 0.64 0.491 
Mean CHA2DS2-VASc score 1.23 0.86 1.65 1.39 1.14 0.309 
 
 
AF, atrial fibrillation; EF, ejection fraction; LA, left atrial; LV, left ventricular; CB, 
cryoballoon; PVAC, pulmonary vein ablation catheter;  
  
Table 2. Procedural parameters 
 
Procedural 
parameters 
CB 
n=13 
PVAC I 
n=7 
PVAC II 
n=37 
PVAC III 
n=18 
nMARQ 
n=14 
p 
Total procedure 
time(min)(SD) 
126 (24) 89 (23) 88 (16) 86(25) 108 (25) <0.001 
Fluoroscopy time (min) 
(SD) 
28.8 (8) 17.7 (8.4) 21.2 (8.8) 16.5 (5.3) 21.1(7.8) 0.002 
Energy delivery time 
(min) (SD) 
34.2 (18.8) 16 (4.5) 14.9 (4.1) 12(2.8) 7.7(3.4) <0.001 
Left atrial access time 
(min) (SD) 
80.8 (26) 70.4(22.7) 55.4 (15.1) 47.2(13.6) 75.9 (27.4) <0.001 
Intraprocedural ACT 
(s) 
340 380 358 328 317 0.148 
Acute success rate (% 
of  isolated PVs) 
98 100 
 
100 
 
100 
 
98  
 
PV, pulmonary vein; other abreviations as above 
 
 
 
 
 
 
  
FIGURE LEGENDS 
 
Figure 1. Bilateral Multifrequency Transcranial Doppler Monitoring of the Middle Cerebral 
Arteries  
(a) Demonstration of beam alignment of both right and left sided MCA and ACA. Continuous 
yellow line indicates the location of monitoring at 55 mm insonation depth (MCA).  
(b) MCA waveform.  
Arrows on right panel indicate the high intensity transient signals corresponding to cerebral 
microemboli during PV angiography. 
MCA, middle cerebral artery; ACA, anterior cerebral artery 
 
Figure 2. Left panel: Total Microembolic Signal Count in the Five Treatment Groups. A plot 
of the mean number of microembolic signals (MESs) per middle cerebral artery in each 
treatment group, as compared with the CB group. 
Right panel: Ratio of Gaseous/Solid Emboli in the Five Treatment Groups.  
(Abrevations as in tables) 
  
 
Figure 3.  Microembolic Signal Counts During Different Stages of the Procedure. 
(Abrevations as above)   
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